Re-Named Melinta Moving Ahead With Delafloxacin And Novel Class Of Antibiotics

Formerly known as Rib-X Pharmaceuticals, Connecticut biotech reacquires rights to RX-04 antibiotic platform from Sanofi and moves forward with venture backing from Vatera and new management team.